seed
Stage
1
Investors
About
OVO Biomanufacturing provides a cloud-based software platform that analyses Next Generation Sequencing (NGS) data to identify and manage defective interfering particles (DIPs) during viral vaccine manufacturing, helping manufacturers optimise working seed stocks and improve final vaccine yields for live attenuated and inactivated vaccines.
Explore OVO Biomanufacturing's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.